Academe Learn
CBME Curriculum Preview

Page 34 of 34

PH7.1-9 | Endocrine Pharmacology — PBL Case

CLINICAL SETTING

Dr. Praveen is the on-call medical registrar at a district hospital in Andhra Pradesh. He is called to see Smt. Kamakshi, a 54-year-old vegetable farmer, who has been brought in by her daughter. The daughter says, 'Doctor, my mother has been taking steroid tablets for her knee swelling for two years from a local practitioner. She stopped them suddenly three days ago when someone told her they were bad for her. Now she is very weak, cannot stand, and is vomiting.' On further questioning, Kamakshi says she has been gaining weight gradually for three years, her skin has become very dry, and she feels cold even in summer. She has not seen a doctor in the last five years. Vitals: BP 86/52 mmHg, HR 56/min (regular), temperature 36.1°C. She is drowsy but arousable.

Trigger 1: The Collapse

Kamakshi is drowsy, unable to stand, and her BP is 86/52 mmHg. She had been taking prednisolone 10 mg daily for two years for 'knee pain and swelling' prescribed by a local practitioner, and stopped abruptly three days ago. Her daughter brings a strip of prednisolone tablets as evidence. Blood glucose: 52 mg/dL (hypoglycaemia). Sodium: 129 mEq/L (hyponatraemia). Potassium: 5.8 mEq/L (hyperkalaemia). The nurse asks Dr. Praveen: 'Sir, what is happening to her? Should we give her sugar?'

DISCUSSION POINTS

  • What is the most likely diagnosis to explain the combination of hypotension, hyponatraemia, hyperkalaemia, and hypoglycaemia in a patient who abruptly stopped long-term corticosteroids?
  • Explain, using the HPA axis physiology, why abrupt discontinuation of long-term prednisolone causes this clinical state.
  • What is the immediate pharmacological intervention? Name the drug, dose, route, and formulation — and justify why oral supplementation is inadequate here.
  • Why does long-term prednisolone administration suppress endogenous cortisol production even after the drug is stopped?
Click to reveal Trigger 2: The Deeper Picture (discuss previous trigger first!)

Trigger 2: The Deeper Picture

IV hydrocortisone 100 mg is given stat. Within 4 hours, Kamakshi's BP improves to 102/68 mmHg and she becomes fully alert. Dr. Praveen now takes a detailed history and examines her properly. He notices: dry, rough, doughy skin; coarse hair; slow speech; delayed relaxation phase of deep tendon reflexes; periorbital puffiness; non-pitting oedema of the legs. She has had these symptoms for 3 years. She reports chronic constipation and heavy periods (now post-menopausal). Blood results return: TSH 42 mIU/L (markedly elevated), free T4 0.4 ng/dL (very low). ECG shows low-voltage complexes with sinus bradycardia.

DISCUSSION POINTS

  • What is the second diagnosis? Correlate each clinical feature (bradycardia, low-voltage ECG, doughy oedema, delayed DTR relaxation) with the underlying physiology of thyroid hormone deficiency.
  • She requires levothyroxine. Why must you start at a very low dose (e.g., 12.5–25 mcg/day) and escalate slowly — what is the pharmacological danger of starting at full replacement dose?
  • Explain the drug interaction between her corticosteroid replacement and levothyroxine — specifically, what physiological change does adequate thyroid replacement cause that could unmask a new crisis in this patient?
  • What monitoring plan (drug level / blood test / timing) would you follow for her levothyroxine replacement?
Click to reveal Trigger 3: The Discharge Dilemma (discuss previous trigger first!)

Trigger 3: The Discharge Dilemma

After 5 days, Kamakshi is stable and ready for discharge. Her final medication plan includes: hydrocortisone 15 mg + 5 mg BD (replacement doses), levothyroxine 25 mcg daily (to be escalated), calcium 1 g daily, and vitamin D 800 IU. Her DXA scan (obtained during admission) shows a T-score of −2.6 at the femoral neck. Her daughter asks: 'Doctor, will she have to take steroids for life? Are steroids not bad for the bones?' Dr. Praveen must counsel the family and write discharge prescriptions.

DISCUSSION POINTS

  • Is lifelong corticosteroid replacement appropriate here? Explain the distinction between pharmacological doses (used for anti-inflammatory treatment) and physiological replacement doses (used for adrenal insufficiency) — and the risk profile difference.
  • Her DXA T-score is −2.6. Given that she is on long-term corticosteroids and has a T-score in the osteopenia/osteoporosis range, what pharmacological measure should you prescribe to prevent further bone loss? Justify your drug choice, considering her clinical context.
  • Construct an integrated counselling message for the daughter covering: (a) why steroids are necessary and safe at replacement doses; (b) how levothyroxine should be taken (timing and interactions); (c) one warning sign that should prompt immediate return to the hospital.
  • What is the 'sick day rule' for patients on corticosteroid replacement, and why is it pharmacologically important?

Group Task Assignments

Group 1: HPA Axis Physiology and Adrenal Crisis Mechanism

  • Draw and explain the HPA negative feedback loop under normal conditions
  • Explain how prolonged exogenous glucocorticoid use suppresses ACTH → adrenal cortex atrophy → inability to respond to stress
  • Present a 3-step mechanism for why abrupt corticosteroid withdrawal causes the triad of hypotension, hyponatraemia, hyperkalaemia

Competencies: PH7.5

Group 2: Pharmacology of Corticosteroids — Types, Potency, and ADRs

  • Prepare a comparison table of 5 corticosteroids (hydrocortisone, prednisolone, methylprednisolone, dexamethasone, fludrocortisone) with GC potency, MC potency, and clinical indications
  • Explain the major adverse effects of long-term corticosteroid use on 4 organ systems
  • Describe the tapering protocol and sick-day rule for patients on long-term steroids

Competencies: PH7.5

Group 3: Thyroid Pharmacology — Replacement, Monitoring, and Drug Interactions

  • Explain levothyroxine pharmacokinetics (absorption, T½, T4→T3 conversion) and the rationale for morning fasting dosing
  • List and explain 4 drug/food interactions that reduce levothyroxine absorption or metabolism
  • Explain why levothyroxine must be started at low doses in adrenal insufficiency and cardiac patients — the pharmacological interaction mechanism

Competencies: PH7.3

Group 4: Osteoporosis Prevention in Corticosteroid-Treated Patients

  • Explain the mechanism of glucocorticoid-induced osteoporosis (GIOP) — RANK-L/OPG, osteoblast suppression, calcium absorption
  • Describe the pharmacological prevention protocol (calcium + vitamin D + bisphosphonate/denosumab) with specific doses and monitoring
  • Discuss how to choose between alendronate and denosumab in a patient with eGFR restriction

Competencies: PH7.2, PH7.5

Group 5: Patient Counselling and Communication

  • Develop a structured patient information sheet (in simple language) covering: when to take levothyroxine, how to take corticosteroids safely, and warning signs of adrenal crisis
  • Role-play the discharge counselling conversation between Dr. Praveen and Kamakshi's daughter — covering the sick day rule, drug timing, and when to seek emergency care
  • Identify and address 2 common misconceptions about steroid use in Indian patients (e.g., 'all steroids are bad', 'stop steroids when you feel better')

Competencies: PH7.5, PH7.3

Learning Issues

Research these questions and bring your findings to the discussion.

  1. [PH7.5] What are the physiological effects of glucocorticoids on the HPA axis, and how does prolonged pharmacological use lead to adrenal suppression and crisis on withdrawal?
  2. [PH7.5] Describe the classification, relative potencies, and adverse effects of corticosteroids, and explain the principles of safe tapering and sick-day dosing.
  3. [PH7.3] What is the pharmacokinetic basis of levothyroxine dosing and monitoring, and what drug/food interactions must be avoided?
  4. [PH7.3] Why must levothyroxine initiation be slow in a patient with concurrent adrenal insufficiency — what is the interaction mechanism and how is it managed?
  5. [PH7.2] What is glucocorticoid-induced osteoporosis (GIOP) and how should it be prevented and treated, particularly in patients with reduced renal function?